Cellectar Biosciences announced recently a clinical benefit rate of 80 percent from its Phase I clinical study of CLR 131 in patients with relapsed or refractory multiple myeloma.
“The efficacy observed with CLR 131 at the 12.5 and 18.75 mCi/m2 single dose compares favorably to drugs recently approved for relapsed or refractory multiple myeloma. We believe that the 18.75 mCi/m2 dose could represent an acceptable single dose or multi-dose regimen for future studies,” Cellectar Biosciences CEO Jim Caruso said in a statement. “Combined with its clean safety profile, we are optimistic regarding the potential of CLR 131 and look forward to seeing results from our recently initiated Cohort 3 at a single 25mCi/m2 dose.”
According to a release, the patients from the first cohort have a post-treatment median survival rate of 11.9 months, which is an improvement with other myeloma treatments. However, not enough data exists to determine the effect of CLR 131 on overall survival benefit.
The biotechnology company is currently seeking participants for its third cohort.
